PET Imaging of Phosphodiesterases in Brain

Research output: Contribution to report/book/conference proceedingsChapter

Standard

PET Imaging of Phosphodiesterases in Brain. / Ooms, Maarten; Bormans, Guy.

PET and SPECT of Neurobiological Systems. 2021. ed. Springer International Publishing, 2021. p. 851-877.

Research output: Contribution to report/book/conference proceedingsChapter

Harvard

Ooms, M & Bormans, G 2021, PET Imaging of Phosphodiesterases in Brain. in PET and SPECT of Neurobiological Systems. 2021 edn, Springer International Publishing, pp. 851-877. https://doi.org/10.1007/978-3-030-53176-8_23

APA

Ooms, M., & Bormans, G. (2021). PET Imaging of Phosphodiesterases in Brain. In PET and SPECT of Neurobiological Systems (2021 ed., pp. 851-877). Springer International Publishing. https://doi.org/10.1007/978-3-030-53176-8_23

Vancouver

Ooms M, Bormans G. PET Imaging of Phosphodiesterases in Brain. In PET and SPECT of Neurobiological Systems. 2021 ed. Springer International Publishing. 2021. p. 851-877 https://doi.org/10.1007/978-3-030-53176-8_23

Author

Ooms, Maarten ; Bormans, Guy. / PET Imaging of Phosphodiesterases in Brain. PET and SPECT of Neurobiological Systems. 2021. ed. Springer International Publishing, 2021. pp. 851-877

Bibtex - Download

@inbook{ff716ab03e2c47ada428dff6ced75492,
title = "PET Imaging of Phosphodiesterases in Brain",
abstract = "Phosphodiesterases (PDEs) regulate the intracellular concentration of the secondary messengers cGMP and cAMP thereby modulating a variety of cellular activities in brain. Eleven different families of PDEs have been identified of which at least six show significant expression in brain. Phosphodiesterase inhibitors have been evaluated clinically as potential drugs for treatment of different CNS diseases but so far, no PDE inhibitor has been registerered as a drug for treatment of a CNS disease. PET ligands have been developed and evaluated targeting PDE2,4,5, and 10 and clinical PET studies were conducted with radiolabeled PDE2, 4, and 10 inhibitors. PDEs are interesting targets for in vivo imaging with PET as both their expression level and affinity for inhibitors can be modulated. This chapter provides an overview of the development of PDE PET tracers and their application in preclinical and clinical research.",
keywords = "Phosphodiesterases, Brain imaging, PET",
author = "Maarten Ooms and Guy Bormans",
note = "Score=10",
year = "2021",
month = "1",
day = "3",
doi = "10.1007/978-3-030-53176-8_23",
language = "English",
isbn = "978-3-030-53175-1",
pages = "851--877",
booktitle = "PET and SPECT of Neurobiological Systems",
publisher = "Springer International Publishing",
edition = "2021",

}

RIS - Download

TY - CHAP

T1 - PET Imaging of Phosphodiesterases in Brain

AU - Ooms, Maarten

AU - Bormans, Guy

N1 - Score=10

PY - 2021/1/3

Y1 - 2021/1/3

N2 - Phosphodiesterases (PDEs) regulate the intracellular concentration of the secondary messengers cGMP and cAMP thereby modulating a variety of cellular activities in brain. Eleven different families of PDEs have been identified of which at least six show significant expression in brain. Phosphodiesterase inhibitors have been evaluated clinically as potential drugs for treatment of different CNS diseases but so far, no PDE inhibitor has been registerered as a drug for treatment of a CNS disease. PET ligands have been developed and evaluated targeting PDE2,4,5, and 10 and clinical PET studies were conducted with radiolabeled PDE2, 4, and 10 inhibitors. PDEs are interesting targets for in vivo imaging with PET as both their expression level and affinity for inhibitors can be modulated. This chapter provides an overview of the development of PDE PET tracers and their application in preclinical and clinical research.

AB - Phosphodiesterases (PDEs) regulate the intracellular concentration of the secondary messengers cGMP and cAMP thereby modulating a variety of cellular activities in brain. Eleven different families of PDEs have been identified of which at least six show significant expression in brain. Phosphodiesterase inhibitors have been evaluated clinically as potential drugs for treatment of different CNS diseases but so far, no PDE inhibitor has been registerered as a drug for treatment of a CNS disease. PET ligands have been developed and evaluated targeting PDE2,4,5, and 10 and clinical PET studies were conducted with radiolabeled PDE2, 4, and 10 inhibitors. PDEs are interesting targets for in vivo imaging with PET as both their expression level and affinity for inhibitors can be modulated. This chapter provides an overview of the development of PDE PET tracers and their application in preclinical and clinical research.

KW - Phosphodiesterases

KW - Brain imaging

KW - PET

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/40682436

U2 - 10.1007/978-3-030-53176-8_23

DO - 10.1007/978-3-030-53176-8_23

M3 - Chapter

SN - 978-3-030-53175-1

SP - 851

EP - 877

BT - PET and SPECT of Neurobiological Systems

PB - Springer International Publishing

ER -

ID: 6939084